Acute Respiratory Distress Syndrome Pipeline Outlook Report 2024 (Updated)

DelveInsight's, "Acute Respiratory Distress Syndrome Pipeline Insight, 2024," report provides comprehensive insights about 50+ companies and 50+ pipeline drugs in Acute Respiratory Distress Syndrome pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Key Takeaways from the Acute Respiratory Distress Syndrome Pipeline Report
• Over 50+ Acute Respiratory Distress Syndrome companies are evaluating 50+ Acute Respiratory Distress Syndrome pipeline therapies in various stages of development, and their anticipated acceptance in the Acute Respiratory Distress Syndrome market would significantly increase market revenue.
• The leading Acute Respiratory Distress Syndrome Companies include Faron Pharmaceuticals, BioMarck Pharmaceuticals, Athersys, Apeiron Biologics, Cynata Therapeutics, Orbsen Therapeutics, GEn1E Lifesciences, Exvastat, Longeveron, CohBar, ZyVersa Therapeutics, Abbreos, Aviceda Therapeutics, ImStem Biotechnology, Bayer, AVM Biotechnology, Cartesian Therapeutics, Sage Therapeutics, Roivant Sciences, ZyVersa Therapeutics, Aerpio Pharmaceuticals, and others.
• Promising Acute Respiratory Distress Syndrome Pipeline Therapies to include MultiStem, TNX-832, HLCM051, ALT-836, Nitric Oxide, ECMO (Quadrox®, Jostra®, Maquet®), glenzocimab, and others.
• March 2024: Boehringer Ingelheim announced a study of Phase 2 & 3 clinical trials for Alteplase low dose and Alteplase high dose. This is a study in adults with severe breathing problems because of COVID-19. People who are in hospital on breathing support can participate in the study. The purpose of the study is to find out whether a medicine called alteplase helps people get better faster.
• March 2024: Dompé Farmaceutici S.p.A announced a study of Phase 2 clinical trials for Reparixin 600mg. To characterize the efficacy of reparixin in ameliorating lung injury and systemic inflammation and expediting clinical recovery and liberation from mechanical ventilation in adult patients with moderate to severe ARDS (PaO2/FIO2 ratio ≤ 200).

Request a sample and discover the recent breakthroughs happening in the Acute Respiratory Distress Syndrome Pipeline landscape @ Acute Respiratory Distress Syndrome Pipeline Outlook Report- https://www.delveinsight.com/sample-request/acute-respiratory-distress-syndrome-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

In the Acute Respiratory Distress Syndrome pipeline report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, Acute Respiratory Distress Syndrome NDA approvals (if any), and product development activities comprising the technology, Acute Respiratory Distress Syndrome collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Acute Respiratory Distress Syndrome Overview
ARDS is a rapidly progressive disease occurring in critically ill patients. The major complication in ARDS is marked by leakage of fluid into the lungs, making breathing difficult or impossible. It is a severe lung condition that causes low blood oxygen. People who develop ARDS are usually ill due to another disease or a major injury which leads to fluid build-up inside the tiny air sacs of the lungs, and surfactant breakdown.

Find out more about Acute Respiratory Distress Syndrome Therapeutics Assessment @ Acute Respiratory Distress Syndrome Preclinical and Discovery Stage Products- https://www.delveinsight.com/sample-request/acute-respiratory-distress-syndrome-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Acute Respiratory Distress Syndrome Emerging Therapies

STSA 1002: Staidson (Beijing) Biopharmaceuticals Co., Ltd
STSA 1002 is an investigative recombinant anti-human C5a IgG1 monoclonal antibody which acts by targeting complement C5a inhibitors C5a by specifically binding to anaphylatoxin C5a, C5a loses its ability to bind to receptors and blocks C5a-induced Biological functions, such as neutrophil chemotaxis, degranulation and oxygen respiratory burst, etc., while not affecting C5 cleavage and the formation of membrane attack complex (MAC), retaining the bacteriolytic and bactericidal functions of the complement system, thereby achieving the treatment of viruses, etc. Severe pneumonia, acute lung injury or acute respiratory distress syndrome caused by factors. It is administered through oral and subcutaneous route. Currently, the drug is in Phase I/II stage of its development for the treatment of acute respiratory distress syndrome.

Descartes 30: Cartesian Therapeutics
Descartes-30 is an off-the-shelf (allogeneic) MSC product engineered with Cartesian's RNA ArmorySM cell therapy platform. Descartes-30 expresses a unique combination of DNases in patients and delivers a targeted treatment directly to the site of disease which eliminates neutrophil extracellular traps which are a key driver of inflammation and clotting in acute respiratory distress syndrome. The drug candidate relies on cell replacements mechanism of action. Currently the drug is in Phase I/II stage of clinical trial for the treatment of acute respiratory distress syndrome.

GEn 1124: GEn1E Lifesciences
GEn 1124 is an investigative small molecule drug being developed in collaboration with GEn1E Lifesciences and Biomedical Advanced Research and Development Authority (BARDA),part of the Administration for Strategic Preparedness and Response within the U.S. Department of Health and Human Services to support the development of the company's novel therapy for acute respiratory distress syndrome (ARDS), The drug candidate is mitogen activated protein kinase 14 inhibitors .Currently, the drug is in Phase II stage of its development for the treatment of acute respiratory distress syndrome.

ALT-100: Aqualung Therapeutics Corp.
ALT-100 is a "First in Man" immune-based monoclonal antibody (mAb) being developed by Aqualung Therapeutics Corp. ALT-100 antibody is a revolutionary, next generation antibody therapy. The humanized antibody has been developed and optimized by Fusion Antibodies' revolutionary CDRx humanization and ADD develop ability platforms. This humanized monoclonal antibody will block systemic inflammation and will improve survival in the ARDS. ALT-100 inhibits eNAMPT binding to TLR4.Currently the drug is in Phase II stage of clinical trial for the treatment of acute distress respiratory syndrome.

Acute Respiratory Distress Syndrome Therapeutics Assessment
There are approx. 50+ key Acute Respiratory Distress Syndrome companies which are developing the therapies for Acute Respiratory Distress Syndrome. The Acute Respiratory Distress Syndrome companies which have their drug candidates in the most advanced stage, i.e. Phase III include, GEn1E Lifesciences.

DelveInsight's Acute Respiratory Distress Syndrome pipeline report covers around 50+ products under different phases of clinical development like
• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Acute Respiratory Distress Syndrome pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
• Oral
• Parenteral
• Intravitreal
• Subretinal
• Topical

Acute Respiratory Distress Syndrome Products have been categorized under various Molecule types such as
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy

Learn more about the emerging Acute Respiratory Distress Syndrome Pipeline Therapies @ Acute Respiratory Distress Syndrome Clinical Trials Assessment- https://www.delveinsight.com/sample-request/acute-respiratory-distress-syndrome-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Scope of the Acute Respiratory Distress Syndrome Pipeline Report
• Coverage- Global
• Acute Respiratory Distress Syndrome Companies- Faron Pharmaceuticals, BioMarck Pharmaceuticals, Athersys, Apeiron Biologics, Cynata Therapeutics, Orbsen Therapeutics, GEn1E Lifesciences, Exvastat, Longeveron, CohBar, ZyVersa Therapeutics, Abbreos, Aviceda Therapeutics, ImStem Biotechnology, Bayer, AVM Biotechnology, Cartesian Therapeutics, Sage Therapeutics, Roivant Sciences, ZyVersa Therapeutics, Aerpio Pharmaceuticals, and others.
• Acute Respiratory Distress Syndrome Pipeline Therapies- MultiStem, TNX-832, HLCM051, ALT-836, Nitric Oxide, ECMO (Quadrox®, Jostra®, Maquet®), glenzocimab, and others.
• Acute Respiratory Distress Syndrome Pipeline Segmentation: Product Type, Molecule Type, Route of Administration, Mechanism of Action

Dive deep into rich insights for drugs for Acute Respiratory Distress Syndrome Pipeline Companies and Therapies, click here @ Acute Respiratory Distress Syndrome Unmet Needs and Analyst Views- https://www.delveinsight.com/sample-request/acute-respiratory-distress-syndrome-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Table of Content
1. Introduction
2. Executive Summary
3. Acute Respiratory Distress Syndrome: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Acute Respiratory Distress Syndrome - DelveInsight's Analytical Perspective
7. In-depth Commercial Assessment
8. Acute Respiratory Distress Syndrome Collaboration Deals
9. Late Stage Products (Phase III)
10. Traumakine: Faron Pharmaceuticals
11. Drug profiles in the detailed report…..
12. Mid Stage Products (Phase II)
13. BIO-11006: BioMarck Pharmaceuticals
14. Drug profiles in the detailed report…..
15. Early Stage Products (Phase I)
16. GEn1E-1124: GEn1E Lifesciences
17. Drug profiles in the detailed report…..
18. Preclinical/Discovery Stage Products
19. IC 100: ZyVersa Therapeutics
20. Drug profiles in the detailed report…..
21. Inactive Products
22. Acute Respiratory Distress Syndrome Key Companies
23. Acute Respiratory Distress Syndrome Key Products
24. Acute Respiratory Distress Syndrome- Unmet Needs
25. Acute Respiratory Distress Syndrome- Market Drivers and Barriers
26. Acute Respiratory Distress Syndrome- Future Perspectives and Conclusion
27. Acute Respiratory Distress Syndrome Analyst Views
28. Acute Respiratory Distress Syndrome Key Companies
29. Appendix

Got Queries? Find out the related information on Acute Respiratory Distress Syndrome Mergers and acquisitions, Acute Respiratory Distress Syndrome Licensing Activities @ Acute Respiratory Distress Syndrome Recent Trends, and Future Perspectives- https://www.delveinsight.com/sample-request/acute-respiratory-distress-syndrome-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

List of Important Links-

https://faceblox.mn.co/posts/54148443
https://edpt204w19.mn.co/posts/54148617
https://monewment.mn.co/posts/54148939
https://flexi-vegan.mn.co/posts/54149020
https://network-4526.mn.co/posts/54149059
https://redline-rp.mn.co/posts/54149156
https://sparklabsglobal.mn.co/posts/54149234
https://ajodance.mn.co/posts/54149267
https://datingwithprettygirls.mn.co/posts/54149313
https://dazed.mn.co/posts/54149356
https://moons.mn.co/posts/54149384
https://network-339477.mn.co/posts/54149409
https://match-ideas.mn.co/posts/54149766
https://ceo-codes.mn.co/posts/54149864
https://thinkinvestments.mn.co/members/23360451
https://spoder.mn.co/posts/54150026
https://network-64869.mn.co/posts/54150082
https://network-4448412.mn.co/posts/54150397
https://network-90620.mn.co/posts/54150432
https://network-16648.mn.co/posts/54150462
https://a-d-n.mn.co/posts/54150499
https://fcmcommunity.mn.co/posts/54280862
https://good-stewards.mn.co/posts/54280899
https://listening-works.mn.co/posts/54280919
https://network-20540.mn.co/posts/54280968
https://healing-communities-njde.mn.co/posts/54281001
https://runite.mn.co/posts/54281382
https://jasa-seo.mn.co/posts/54281443
https://louhangaround.mn.co/posts/54281497
https://onwayassociation.mn.co/posts/54281510
https://shaman-leaders.mn.co/posts/54281625
https://virtuous-rubies.mn.co/posts/54281637
https://extinct-networks.mn.co/posts/54281691
https://kingnobleblacksupremacy.mn.co/posts/54282200
https://ledpanellights.mn.co/posts/54282336
https://diy-vision.mn.co/posts/54282407
https://digimac-technologies.mn.co/posts/54282475
https://network-89593.mn.co/posts/54282548
https://tdcommunitynetworks.mn.co/posts/54282663
https://machine-parts-toolbox.mn.co/posts/54282718
https://wecanchat.mn.co/posts/exploring-the-dynamics-of-the-uveitis-market-insights-by-delveinsight
https://jointsnmotion-hub.mn.co/posts/54283557
https://artisthub.mn.co/posts/54283657
https://global-non-profit-network.mn.co/posts/54283837
https://jointsnmotion-hub.mn.co/posts/54283943
https://network-5674633.mn.co/posts/54284190
https://where-this-business-and-businesses.mn.co/posts/54284238
https://travelwithme.social/read-blog/34900

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: ybhardwaj@delveinsight.com
Phone: 9650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website:
https://www.delveinsight.com/report-store/medical-marijuana-market-insight
https://www.delveinsight.com/report-store/ranibizumab-biosimilars-insight
https://www.delveinsight.com/report-store/vital-sign-monitors-external-remote-patient-monitoring-devices-market

This release was published on openPR.